Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
RCE
vs
S
S&P/ASX 300
RCE
Over the past 12 months, RCE has underperformed S&P/ASX 300, delivering a return of -26% compared to S&P/ASX 300's 4% drop.
Stocks Performance
RCE vs S&P/ASX 300
Performance Gap
RCE vs S&P/ASX 300
Performance By Year
RCE vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Recce Pharmaceuticals Ltd
Glance View
Recce Pharmaceuticals is an Australian drug-development company focused on new treatments for serious infections. Its main work is to design and test synthetic anti-infective drugs aimed at bacteria, viruses, and fungi, especially infections that are hard to treat with existing medicines. The company is still in development mode, so it does not sell a broad portfolio of approved drugs like a big pharma company would. Its lead products are drug candidates built around the RECCE platform, which the company develops through laboratory testing and clinical studies. The main customers for this kind of business are not patients directly but hospitals, doctors, governments, and larger drug companies if the products are eventually licensed or partnered. Recce makes money in the usual biotech way: by advancing its compounds, seeking regulatory approval, and then earning revenue through product sales, licensing deals, partnerships, or development funding if a drug reaches the market. What makes Recce different is its focus on anti-infective drugs rather than broad medical technology or general therapeutics. That puts it in a specialized corner of the pharmaceutical industry where the value is often tied to solving drug resistance and difficult-to-treat infections. Investors should think of it as a research-driven biotech whose business depends on proving that its compounds can become useful medicines and then turning that science into commercial deals.
